NATIONAL COMPREHENSIVE CANCER NETWORK

† NCCN Guidelines® Category 1, Preferred recommendation applies to AML patients age ≥60 in the post-induction setting who received previous intensive therapy and were unable to receive any of all recommended consolidation, regardless of risk status. For other intermediate or adverse risk AML patients, oral azacitidine (ONUREG®) is a 2A recommended treatment in the post-induction setting, regardless of consolidation status... Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed June 14, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way... The efficacy of ONUREG® was evaluated in QUAZAR® AML-001, a multicenter,..

Also known as: National Cancer Institute, National Comprehensive Cancer Network, Inc, NCCN